National Competition Agency studies prices of medicines for oncologic diseases offered by four pharmaceutical companies based on the data provided by the Health Ministry, said the Agency Chair Irakli Lekvinadze.
According to Lekvinadze, the Competition Agency communicates with the companies to probe into the alleged “Carter agreement” related to offering equal prices within the framework of the state program.
“We should wait for the research results that are expected to be known in 6 months to confirm or reject the suspicion,” he said.
